Fiche centre
Hopital Roger Salengro; Service de Neurologie
Lille — France
Essais liés2clinical trials
VilleLillelocalisation
PaysFrancelocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT02861014
Essais cliniques associés
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Ocrelizumab | SEP | Phase 3 | NCT02861014 | A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) | COMPLETED |
| Ocrelizumab 300 mg | SEP | Phase 4 | NCT03589105 | PRO-MSACTIVE — A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting | COMPLETED |